Gastroenterology
Volume 129, Issue 3 , Pages 995-1004, September 2005

Inhibition of Transient Lower Esophageal Sphincter Relaxation and Gastroesophageal Reflux by Metabotropic Glutamate Receptor Ligands

  • Claudine L. Frisby

      Affiliations

    • Nerve-Gut Research Laboratory, Royal Adelaide Hospital, Adelaide, Australia
  • ,
  • Jan P. Mattsson

      Affiliations

    • R&D Department, AstraZeneca, Mölndal, Sweden
  • ,
  • Jörgen M. Jensen

      Affiliations

    • R&D Department, AstraZeneca, Mölndal, Sweden
  • ,
  • Anders Lehmann

      Affiliations

    • R&D Department, AstraZeneca, Mölndal, Sweden
  • ,
  • John Dent

      Affiliations

    • Nerve-Gut Research Laboratory, Royal Adelaide Hospital, Adelaide, Australia
    • Department of Medicine, University of Adelaide, Adelaide, Australia
  • ,
  • L. Ashley Blackshaw

      Affiliations

    • Nerve-Gut Research Laboratory, Royal Adelaide Hospital, Adelaide, Australia
    • Department of Medicine, University of Adelaide, Adelaide, Australia
    • Discipline of Physiology, University of Adelaide, Adelaide, Australia
    • Corresponding Author InformationAddress requests for reprints to: L. Ashley Blackshaw, PhD, Nerve Gut Research Laboratory, Hanson Institute, Frome Road, Adelaide, SA 5000, Australia.

Received 20 January 2005; accepted 2 June 2005.

Background & Aims: Transient lower esophageal sphincter relaxation (TLESR) is the major mechanism of gastroesophageal acid reflux. TLESR is mediated via vagal pathways, which may be modulated by metabotropic glutamate receptors (mGluRs). Group I mGluRs (mGluR1 and 5) have excitatory effects on neurons, whereas group II (mGluR2 and 3) and group III (mGluR4, 6, 7, and 8) are inhibitory. This study determined the effect of mGluRs on triggering of TLESR and reflux in an established conscious ferret model. Methods: Esophageal manometric/pH studies were performed in ferrets with chronic esophagostomies. TLESR were induced by a gastric load of 25 mL glucose (pH 3.5) and 30 mL air. Results: In control treated animals, gastric load induced 3.52 ± 0.46 TLESRs per 47-minute study, 89.7% of which were associated with reflux episodes (n = 16). The mGluR5 antagonist MPEP inhibited TLESR dose dependently, with maximal 71% ± 7% inhibition at 35 μmol/kg (n = 9; P < .0001). MPEP also significantly reduced reflux episodes (P < .001) and increased basal lower esophageal sphincter pressure (P < .05). MPEP inhibited swallowing dose dependently, suggesting a common action on trigger mechanisms for swallowing and TLESR. The more selective analogue, MTEP, had more potent effects (90% ± 6% inhibition TLESR at 40 μmol/kg; n = 8; P < .0001). In contrast, the group I agonist DHPG tended to increase TLESR. The group II agonist (2R, 4R)-APDC was ineffective, whereas the group III agonist L-(AP4 slightly reduced TLESR (33% at 11 μmol/kg; P < .05). The selective mGluR8 agonist (S)-3, 4-DCPG inhibited TLESR by 54% at 15 μmol/kg (P < .01). Conclusions: mGluR5 antagonists potently inhibit TLESR and reflux in ferrets, implicating mGluR5 in the mechanism of TLESR. mGluR5 antagonists are therefore promising as therapy for patients with GERD.

Abbreviations used in this paper:  GABA, γ-aminobutyric acid , GERD, gastroesophageal reflux disease , L-AP4, L-(+)-2-amino-4-phosphonobutyric acid , mGluR, metabotropic glutamate receptor , MPEP, 2-methyl-6-(phenylethynyl)-pyridine , MTEP, 3-([2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine , NMDA, N-methyl-D-aspartate , (R,S)-3, 5-DHPG,(R,S)-3, 5-dihydroxyphenylglycine , (S)-3, 4-DCPG,(S)-3, 4-dicarboxyphenylglycine , TLESR, transient lower esophageal sphincter relaxation , (2R,4R)-APDC, (2R, 4R)-4-aminopyrrolidine-2, 4-dicarboxylate

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by AstraZeneca R&D (Mölndal, Sweden).

PII: S0016-5085(05)01357-0

doi:10.1053/j.gastro.2005.06.069

Gastroenterology
Volume 129, Issue 3 , Pages 995-1004, September 2005